I also see the wisdom in taking Flucide through the FDA first. It is likely lowest risk to get approved and enables all other cides. After that, the company will be in a much better financial and bargaining position for HIV-cide, for example.
Thanks. Some thoughtful comparisons. Do you think the fact that NNVC is microscopic and has no other products will impair their negotiating position? A big pharma could demand more concessions, taking a "go with us or starve" position.
It seems CTIX is having problems getting trials started despite a very promising new product (due to lack of funding). Is there a valid comparison with NNVC there?
Is there any chance, in your view, that NNVC will try to take Flucide through independently?